Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Increased sales of products for which demand remained solid or strong, selling price revisions in response to higher raw material and fuel prices, the expectation that most shipments of DDS pharmaceutical formulation materials will take place in the second half of the fiscal year, and the recognition of revenue from certain transactions related to initial costs for early equipment deployment in the explosives business.
Not applicable (no matters to report in the notes on the going concern assumption)
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥69,007 million (YoY +23.1%) |
| Operating profit | ¥10,695 million (YoY -9.7%) |
| Ordinary income | ¥11,505 million (YoY -6.3%) |
| Profit attributable to owners of the parent | ¥7,571 million (YoY -12.1%) |
| Net income per share | ¥33.53 |
| Equity ratio | End of the current fiscal period 76.7 / End of previous period 74 |
| Total assets | ¥382,306 million |
| Net assets | ¥294,345 million |
| Full-year earnings forecast | Net Sales ¥319,000 million (YoY +23.7%) / Operating profit ¥50,000 million (YoY +5.5%) / Ordinary income ¥51,000 million (YoY +1.3%) / Net income ¥39,000 million (YoY -3.8%) |
| Annual Dividend Forecast | ¥61 → ¥70 |
| Shareholder Return Policy | Targeting a total payout ratio of at least 70% |
| Segment revenue | ¥39,177 million (YoY +8.8%), ¥11,244 million (YoY -17.9%), ¥18,411 million (YoY +197.8%), ¥174 million (YoY +1.6%) |
| Segment profit | ¥7,852 million (YoY +11.0%), ¥1,223 million (YoY -77.6%), ¥2,296 million, ¥163 million (YoY -1.4%) |
| Regional sales | ¥51,637 million, ¥9,244 million, ¥5,278 million, ¥2,847 million |
| Depreciation and amortization | ¥10,323 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥36 million / Extraordinary loss Loss on Disposal of Fixed Assets ¥79 million |
| Disclosure regarding the going concern assumption | Not applicable (no matters to report in the notes on the going concern assumption) |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | Added: 0 companies; excluded: 0 companies |
| Material subsequent events | Acquisition and cancellation of treasury shares. A resolution was passed to acquire up to 2,000,000 common shares for a maximum of ¥5,000 million and cancel 10,000,000 shares on 30 September 2026. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | None (対象者：Not applicable) |
| Issued Shares at Period-End | 236,524,128 |
| Treasury Shares at Period-End | 11,789,730 |
| Factors Behind Changes in Business Performance | Increased sales of products for which demand remained solid or strong, selling price revisions in response to higher raw material and fuel prices, the expectation that most shipments of DDS pharmaceutical formulation materials will take place in the second half of the fiscal year, and the recognition of revenue from certain transactions related to initial costs for early equipment deployment in the explosives business. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Net sales increased due to higher demand for environment- and energy-related products, toiletries-related products and products for health foods, selling price revisions in response to higher raw material and fuel prices, and the recognition of revenue from certain transactions related to initial costs for early equipment deployment in the explosives business. In the pharmaceutical, medical and healthcare business, net sales and operating income declined because most shipments of DDS pharmaceutical formulation materials are expected in the second half of the fiscal year.